Shenzhen Kangtai Biological Products (300601.SZ): Quadrivalent split influenza vaccine (6-35 months old population) initiates Phase I clinical trial.

Shenzhen Kangtai Biological Products (300601.SZ) announced that the company's quadrivalent influenza virus split vaccine (for ages 6-35 months) has completed preparations for Phase I clinical trials, and has initiated Phase I clinical trials, with the first participant successfully enrolled recently. This quadrivalent influenza virus split vaccine for Phase I clinical trials is suitable for ages 6-35 months, and can stimulate the body to produce immunity against influenza viruses, used to prevent epidemic influenza caused by vaccine-related strains.